Hongshuai Liu

The paper introduces a computer vision framework to analyze fine motor behaviors in HD mice, identifying disease-specific motor signatures and a scoring system to assess therapeutic effects.

This study characterizes the progression of the zQ175DN mouse model of Huntington disease, identifying early biomarkers like brain volume loss and plasma NfL elevation.

This study uses MRI and fluorescence imaging to show impaired glymphatic function in a mouse model of Huntington disease, suggesting it as a potential biomarker and therapeutic target.

This study develops a CRISPR-Cas13d system targeting CAG-expanded HTT RNA in HD models, reducing mutant mRNA and reversing disease phenotypes without significant off-target effects.

This study shows that HTT silencing in premanifest HD mice delays disease onset and slows progression, using CBVa as a noninvasive biomarker.